Synova Healthcare Files Voluntary Petition to Reorganize Under Chapter 11

Published: Dec 19, 2007

MEDIA, Pa., Dec. 19 /PRNewswire-FirstCall/ -- Synova Healthcare Group, Inc. , announced today that it and its four U.S. subsidiaries (collectively, "Synova") have filed voluntary petitions to reorganize under Chapter 11 of the Bankruptcy Code. Synova is seeking to operate its business as a debtor-in-possession pursuant to the Bankruptcy Code.

Under the Bankruptcy Code, Synova is prohibited from paying pre-petition obligations until a plan of reorganization has been approved by creditors and the bankruptcy court. This prohibition applies to all of Synova's pre- petition obligations, including obligations to holders of its senior convertible promissory notes.

The Company's decision to reorganize under Chapter 11 was made primarily to address Synova's liquidity and capital resources issues, which left Synova unable to continue to effectively operate its business of developing, distributing, marketing and selling innovative over-the-counter women's healthcare products. Synova has historically relied upon equity and debt capital to fund its ongoing operations, and its current inability to locate and obtain such capital severely depleted its cash and other capital resources.

The Chapter 11 petitions were filed in the U.S. Bankruptcy Court in the District of Delaware.

About Synova Healthcare Group, Inc.:

Through its subsidiaries, Synova Healthcare Group, Inc. is focused on the development, distribution, marketing and sale of women's healthcare products related to contraception, vaginal health, menopause management, fertility planning, obstetrics and personal care. Synova's goal is to provide healthcare solutions that address every stage of a woman's reproductive life. Synova markets and sells products under the brand names Today(R) and Fem-V(R). The Today(R) Sponge is a non-hormonal contraceptive that combines barrier, spermicidal and absorptive methods to prevent conception. Fem-V(R) is a non- invasive diagnostic test with 91% sensitivity and is designed to detect the presence of elevated vaginal acidity, assisting women in identifying the most appropriate treatment for vaginal infections. For more information, please visit Synova's website at

Forward-Looking Statements:

Some of the information in this press release may contain "forward-looking statements" within the meaning of the federal securities laws. These forward- looking statements can be identified by forward-looking words such as "may," "will," "expect," "intend," "anticipate," "believe," "estimate," "plan," "could," "should" and "continue" or similar words. These forward-looking statements may also use different phrases. These forward-looking statements are not historical in nature and include statements that reflect, when made, Synova's views with respect to current events and financial performance. All such forward-looking statements are and will be subject to numerous risks, uncertainties and factors relating to Synova's operations and business environment, many of which are beyond Synova's control, that could cause actual results to differ materially from any results expressed or implied by such statements.

Factors that could cause actual results to differ materially include, without limitation:

These statements speak only as of the date of this press release, and Synova disclaims any intention or obligation to update or revise any forward- looking statements to reflect new information, future events or developments or otherwise, except as required by law. Synova provides additional information in its filings with the Securities and Exchange Commission, which readers are encouraged to review, concerning other factors that could cause actual results to differ materially from those indicated in the forward- looking statements.

Similarly, these and other factors, including the terms of any reorganization plan or other alternative transactions ultimately confirmed, can affect the value of Synova's existing common stock or other securities. There has been no determination, and no assurance can be given, as to what values, if any, will be ascribed in the Chapter 11 proceeding to Synova's existing common stock or other securities. Accordingly, Synova urges that the appropriate caution be exercised with respect to existing and future investments in Synova's common stock or other securities.

CONTACT: Robert Edwards, Chief Financial Officer of Synova Healthcare
Group, Inc., +1-610-565-7080,

Web site:

Back to news